The Food and Drug Administration has delayed by three months its decision on what could be the first vaccine available in the U.S. for chikungunya virus.
In an announcement Monday, French vaccine maker Valneva said the FDA extended an evaluation of its shot to the end of November. The regulator was expected to decide whether to grant the vaccine an “accelerated” approval by August 31.
